1. Cell Biology
  2. Stem Cells and Regenerative Medicine

Modeling the ACVR1R206H mutation in human skeletal muscle stem cells

  1. Emilie Barruet  Is a corresponding author
  2. Steven M Garcia
  3. Jake Wu
  4. Blanca M Morales
  5. Stanley Tamaki
  6. Tania Moody
  7. Jason H Pomerantz
  8. Edward C Hsiao  Is a corresponding author
  1. University of California, San Francisco, United States
https://doi.org/10.7554/eLife.66107
Share this article
Cite this article
  1. Emilie Barruet
  2. Steven M Garcia
  3. Jake Wu
  4. Blanca M Morales
  5. Stanley Tamaki
  6. Tania Moody
  7. Jason H Pomerantz
  8. Edward C Hsiao
(2021)
Modeling the ACVR1R206H mutation in human skeletal muscle stem cells
eLife 10:e66107.
https://doi.org/10.7554/eLife.66107
  2. Download BibTeX
  3. Download .RIS

Abstract

Abnormalities in skeletal muscle repair can lead to poor function and complications such as scarring or heterotopic ossification (HO). Here, we use fibrodysplasia ossificans progressiva (FOP), a disease of progressive HO caused by ACVR1R206H (Activin receptor type-1 receptor) mutation, to elucidate how ACVR1 affects skeletal muscle repair. Rare and unique primary FOP human muscle stem cells (Hu-MuSCs) isolated from cadaveric skeletal muscle demonstrated increased ECM marker expression, showed skeletal muscle-specific impaired engraftment and regeneration ability. Human induced pluripotent stem cell (iPSC)-derived muscle stem/progenitor cells (iMPCs) single cell transcriptome analyses from FOP also revealed unusually increased ECM and osteogenic marker expression compared to control iMPCs. These results show that iMPCs can recapitulate many aspects of Hu-MuSCs for detailed in vitro study, that ACVR1 is a key regulator of Hu-MuSC function and skeletal muscle repair; and that ACVR1 activation in iMPCs or Hu-MuSCs may contribute to HO by changing the local tissue environment.

Data availability

Sequencing data have been deposited in GEO under accession codes GSE151918. All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 4,5,6. The dataset used for the primary Hu-MuSCs can be found here, https://datadryad.org/stash/landing/show?id=doi%3A10.7272%2FQ65X273X.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Emilie Barruet

    Departments of Surgery and Orofacial Sciences, Division of Plastic Surgery, Program in Craniofacial Biology, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, San Francisco, United States
    For correspondence
    emilie.barruet@ucsf.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4593-024X

  2. Steven M Garcia

    Departments of Surgery and Orofacial Sciences, Division of Plastic Surgery, Program in Craniofacial Biology, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7833-6677

  3. Jake Wu

    Departments of Surgery and Orofacial Sciences, Division of Plastic Surgery, Program in Craniofacial Biology, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.

  4. Blanca M Morales

    Institute for Human Genetics, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.

  5. Stanley Tamaki

    Departments of Surgery and Orofacial Sciences, Division of Plastic Surgery, Program in Craniofacial Biology, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.

  6. Tania Moody

    Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.

  7. Jason H Pomerantz

    Departments of Surgery and Orofacial Sciences, Division of Plastic Surgery, Program in Craniofacial Biology, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5107-1883

  8. Edward C Hsiao

    Division of Endocrinology and Metabolism, Department of Medicine Institute for Human Genetics, University of California, San Francisco, San Francisco, United States
    For correspondence
    Edward.Hsiao@ucsf.edu
    Competing interests
    Edward C Hsiao, ECH receives clinical trial research funding from Clementia Pharmaceuticals, an Ipsen company, and Neurocrine Biosciences, Inc., through his institution. ECH received prior funding from Regeneron Pharmaceuticals, through his institution. ECH serves in an unpaid capacity on the international FOP Association Medical Registry Advisory Board, on the International Clinical Council on FOP, and on the Fibrous Dysplasia Foundation Medical Advisory Board. These activities pose no conflicts for the presented research..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8924-106X

Funding

National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR066735)

  • Edward C Hsiao

French Muscular Association (Trampoline grant)

  • Emilie Barruet
  • Edward C Hsiao

Radiant Hope Foundation

  • Edward C Hsiao

UCSF Cohort Development Grant

  • Edward C Hsiao

California Institute for Regenerative Medicine (TG2-01153)

  • Emilie Barruet

UCSF Program for Breakthrough Biomedical Research

  • Emilie Barruet

National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR072638-03)

  • Jason H Pomerantz

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All mouse studies were performed using protocols approved by the UCSF Institutional Animal Care and Use Committee. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (AN181101-02A) of the University of California, San Francisco.

Human subjects: Human samples were collected through the University of California - San Francisco Biospecimens and Skeletal Tissues for Rare and Orphan Disease Genetics (BSTROnG) Biobank, using protocols approved by the UCSF Institutional Review Board (10-03053 and 11-06711). All participants provided written consent, which includes consent to collect, use, and publish research data.

Copyright

© 2021, Barruet et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,121
    views
  • 178
    downloads
  • 6
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

Share this article

https://doi.org/10.7554/eLife.66107

Categories and tags

Research organism

Further reading

    1. Cancer Biology
    2. Cell Biology

    Cytosolic and endoplasmic reticulum chaperones inhibit wt-p53 to increase cancer cells' survival by refluxing ER-proteins to the cytosol

    Salam Dabsan, Gali Zur ... Aeid Igbaria
    Research Article

    The endoplasmic reticulum (ER) is an essential sensing organelle responsible for the folding and secretion of almost one-third of eukaryotic cells' total proteins. However, environmental, chemical, and genetic insults often lead to protein misfolding in the ER, accumulating misfolded proteins, and causing ER stress. To solve this, several mechanisms were reported to relieve ER stress by decreasing the ER protein load. Recently, we reported a novel ER surveillance mechanism by which proteins from the secretory pathway are refluxed to the cytosol to relieve the ER of its content. The refluxed proteins gain new prosurvival functions in cancer cells, thereby increasing cancer cell fitness. We termed this phenomenon ER to CYtosol Signaling (or ‘ERCYS’). Here, we found that in mammalian cells, ERCYS is regulated by DNAJB12, DNAJB14, and the HSC70 cochaperone SGTA. Mechanistically, DNAJB12 and DNAJB14 bind HSC70 and SGTA - through their cytosolically localized J-domains to facilitate ER-protein reflux. DNAJB12 is necessary and sufficient to drive this phenomenon to increase AGR2 reflux and inhibit wt-p53 during ER stress. Mutations in DNAJB12/14 J-domain prevent the inhibitory interaction between AGR2-wt-p53. Thus, targeting the DNAJB12/14-HSC70/SGTA axis is a promising strategy to inhibit ERCYS and impair cancer cell fitness.

    1. Cancer Biology
    2. Cell Biology

    N6-methyladenosine in DNA promotes genome stability

    Brooke A Conti, Leo Novikov ... Mariano Oppikofer
    Research Article

    DNA base lesions, such as incorporation of uracil into DNA or base mismatches, can be mutagenic and toxic to replicating cells. To discover factors in repair of genomic uracil, we performed a CRISPR knockout screen in the presence of floxuridine, a chemotherapeutic agent that incorporates uracil and fluorouracil into DNA. We identified known factors, such as uracil DNA N-glycosylase (UNG), and unknown factors, such as the N6-adenosine methyltransferase, METTL3, as required to overcome floxuridine-driven cytotoxicity. Visualized with immunofluorescence, the product of METTL3 activity, N6-methyladenosine, formed nuclear foci in cells treated with floxuridine. The observed N6-methyladenosine was embedded in DNA, called 6mA, and these results were confirmed using an orthogonal approach, liquid chromatography coupled to tandem mass spectrometry. METTL3 and 6mA were required for repair of lesions driven by additional base-damaging agents, including raltitrexed, gemcitabine, and hydroxyurea. Our results establish a role for METTL3 and 6mA in promoting genome stability in mammalian cells, especially in response to base damage.

    1. Cell Biology

    Small-molecule activation of TFEB alleviates Niemann–Pick disease type C via promoting lysosomal exocytosis and biogenesis

    Kaili Du, Hongyu Chen ... Dan Li
    Research Article

    Niemann–Pick disease type C (NPC) is a devastating lysosomal storage disease characterized by abnormal cholesterol accumulation in lysosomes. Currently, there is no treatment for NPC. Transcription factor EB (TFEB), a member of the microphthalmia transcription factors (MiTF), has emerged as a master regulator of lysosomal function and promoted the clearance of substrates stored in cells. However, it is not known whether TFEB plays a role in cholesterol clearance in NPC disease. Here, we show that transgenic overexpression of TFEB, but not TFE3 (another member of MiTF family) facilitates cholesterol clearance in various NPC1 cell models. Pharmacological activation of TFEB by sulforaphane (SFN), a previously identified natural small-molecule TFEB agonist by us, can dramatically ameliorate cholesterol accumulation in human and mouse NPC1 cell models. In NPC1 cells, SFN induces TFEB nuclear translocation via a ROS-Ca2+-calcineurin-dependent but MTOR-independent pathway and upregulates the expression of TFEB-downstream genes, promoting lysosomal exocytosis and biogenesis. While genetic inhibition of TFEB abolishes the cholesterol clearance and exocytosis effect by SFN. In the NPC1 mouse model, SFN dephosphorylates/activates TFEB in the brain and exhibits potent efficacy of rescuing the loss of Purkinje cells and body weight. Hence, pharmacological upregulating lysosome machinery via targeting TFEB represents a promising approach to treat NPC and related lysosomal storage diseases, and provides the possibility of TFEB agonists, that is, SFN as potential NPC therapeutic candidates.